Edgewise Therapeutics, Inc.
EWTX
Rangering i aksjer
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aksjekurs
$38.12
Sist synkronisert: 2026-10-19
Markedsverdi
$4.10B
Endring (1 dag)
2.50%
Endring (1 år)
147.69%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Inntekter for Edgewise Therapeutics, Inc. (EWTX)
Inntekter i Jun 2026 TTM: $-197.22M
Ifølge Edgewise Therapeutics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-197.22M. I 2023 hadde selskapet et resultat på $-100.16M, en nedgang sammenlignet med resultatet i 2022, som var $-67.64M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Edgewise Therapeutics, Inc. fra 2019 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-197.22M | 47.39% |
| 2024 | $-133.81M | 33.60% |
| 2023 | $-100.16M | 48.08% |
| 2022 | $-67.64M | 57.99% |
| 2021 | $-42.81M | 150.03% |
| 2020 | $-17.12M | 76.43% |
| 2019 | $-9.71M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -2,774.60% |
US
|
|
| $-3.09B | 1,465.24% |
US
|
|
| $-4.02B | 1,936.38% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,089.06% |
NL
|
